Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757163 | 0.93 | PTGS2 (0.54) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL19283111 | 0.89 | PTGS2 (0.50) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL21348716 | 0.86 | MAPT (0.52) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL18530427 | 0.86 | MAPT (0.52) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL28680418 | 0.85 | MAPT (0.52) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL18282354 | 0.84 | MAPT (0.49) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL6478841 | 0.83 | CHRNB2 (0.52) | ALDH1A1MAPTCYP1A2KMT2APOLB | |
| SCHEMBL31615724 | 0.83 | BCL9 (0.52) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL839776 | 0.83 | PTGS2 (0.83) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL11431170 | 0.82 | PLA2G4B (0.68) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1030835-B1 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| CN-1335841-A | N- (iminomethyl) amine derivatives, their preparation, their use as medicaments and pharmaceutical compositions containing them | SOD CONSEILS RECH APPLIC (FR) | 2002-02-13 | — | — | CN | disclosed |
| US-6344570-B1 | ANTISTICKING AGENTS FOR CELLS | ASTRAZENECA UK LIMITED (GB) | 2002-02-05 | — | — | US | disclosed |
| EP-1030835-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024398-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| CN-1131418-A | Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof | GREEN CROSS CORP (JP) | 1996-09-18 | — | — | CN | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PTGS2 266/4885ALDH1A1 2891/4885MAPT 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.